Avista Capital Partners

65 East 55TH Street
New York, NY 10022

Website: avistacap.com

Firm Size

• Assets Under Management (AUM):$4.8 Billion
• Number of Funds:13
• Employees:22
• Firm Type:Private Equity
• Focus Areas: Software & Technology
  Services
  Healthcare
  Energy
  

Description

Avista Capital Partners is a private equity firm headquartered in New York, NY. The firm was founded in 2005 and primarily focuses on investing in healthcare, energy, and other industrial sectors. Avista Capital Partners primarily seeks to acquire and grow middle-market companies through their deep industry knowledge and operational expertise. In the healthcare sector, the firm invests across various sub-sectors, including pharmaceuticals, medical devices, healthcare information technology, and healthcare services. They aim to support companies in expanding their market presence, enhancing their operational efficiency, and driving innovation. Avista Capital Partners' energy investments typically span the entire energy value chain, encompassing oil and gas exploration and production, midstream and energy services, as well as renewable energy and energy transition technologies. The firm seeks to partner with management teams to capitalize on new opportunities arising from the evolving energy market dynamics. In addition to healthcare and energy, Avista Capital Partners also invests in select industrial sectors, such as chemicals, metals, and automotive components. They look for companies that demonstrate strong growth potential and offer value creation opportunities through operational improvements, strategic acquisitions, and market expansion. Overall, Avista Capital Partners is recognized for its ability to drive value in investments by leveraging its deep industry knowledge, extensive network, and hands-on approach. The firm has a track record of successfully partnering with management teams, fostering growth, and achieving attractive returns for its investors.

Latest News

Powered by

Mar 01, 2024: AVISTA HEALTHCARE PARTNERS VI CLOSES ON $1.5 BILLION
Avista Capital Partners ("Avista" or "the Firm"), a leading New York -based private equity firm focused exclusively on healthcare, today announced the final closing of Avista Healthcare Partners VI ("Fund VI" or the "Fund") at $1.5 billion . The Fund, which significantly exceeded its $1.25 billion target, represents one of the largest pools of private capital focused on investments across high-growth middle-market product and technology healthcare companies in North America and Europe .

Feb 16, 2024: Avista Capital Partners Acquires Terrats Medical from Miura Partners
Avista Capital Partners ("Avista") today announced its acquisition of  Terrats Medical ("Terrats" or the "Company"), a leading global provider of dental prosthetics, including abutments and implants, from Miura Partners ("Miura"). As part of the transaction, Terrats' founders have reinvested in the Company and will continue to lead the business. Miura has also re-invested in the Company and will continue to support Terrats in the next phase of its growth.

Jan 02, 2024: Fred Duchin Joins Avista Capital Partners as a Strategic Executive
Avista Capital Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced that Fred Duchin has joined the firm as a Strategic Executive. Mr. Duchin is the Chairman of WellSpring Consumer Healthcare and recently joined the Board of Directors of Vision Healthcare. Both WellSpring and Vision are current Avista portfolio companies.

Apr 04, 2023: WellSpring Consumer Healthcare Acquires Iconic OTC Skin Care Brands from Bayer
WellSpring Consumer Healthcare, a developer and marketer of leading over-the-counter and personal care brands, today announced the acquisition of a portfolio of well-recognized and trusted over-the-counter (OTC) skin care brands from Bayer AG. Financial terms of the transaction were not disclosed. WellSpring Consumer Healthcare is a portfolio company of Avista Capital Partners, a leading middle-market healthcare private equity firm with expertise in building OTC platforms.